Q: What is Ajovy used for?

Ajovy is used to treat migraine prevention .

Q: What are the active ingredients in Ajovy?

The active ingredient in Ajovy is fremanezumab .

Q: What drug class is Ajovy?

Ajovy belongs to the CGRP antagonist drug class.

Q: What is the dosage of Ajovy and how do I take it?

Administration Ajovy is given as a subcutaneous injection, which means it is injected into the fatty tissue just under the skin. It is available as a single-dose pre-filled syringe or a pre-filled autoinjector. Common injection sites include the abdomen, the front of the thighs, or the back of the upper arms. Do not inject into areas where the skin is tender, bruised, red, or hard. Frequency This medication is typically used according to one of two schedules: One injection once every month. Three injections given together once every three months. Preparation and Use Before using Ajovy, remove it from the refrigerator and allow it to sit at room temperature for at least 30 minutes. Do not shake the medication or warm it using a microwave or hot water. Check the liquid to ensure it is clear to slightly yellow and free of particles. If you are injecting multiple doses at once for a quarterly schedule, use a different injection site for each syringe. Missed Dose If a dose is missed, it should be administered as soon as possible. After taking the missed dose, the next dose should be scheduled based on the date the last injection was actually given. Do not take a double dose to make up for a missed one.

Q: Is Ajovy safe during pregnancy and breastfeeding?

Pregnancy It is not yet known if Ajovy will harm an unborn baby. There are no adequate or well-controlled studies of Ajovy use in pregnant women to determine drug-associated risks. In animal studies, no evidence of harm to the fetus was observed when the medication was administered during pregnancy. However, because Ajovy is a monoclonal antibody, it may be transferred from the mother to the fetus as the pregnancy progresses. Breastfeeding It is unknown whether Ajovy passes into human breast milk, how it affects milk production, or if it has any effect on a nursing infant. Because many medications can be excreted in human milk, you should consult your healthcare provider to weigh the benefits of breastfeeding against the potential risks to the child. Consulting Your Doctor If you are pregnant, planning to become pregnant, or breastfeeding, talk to your healthcare team before using this medication. They can help you evaluate your specific situation and determine the most appropriate course of treatment.

Q: What is the FDA approval status of Ajovy?

FDA Approval and Indications The U.S. Food and Drug Administration (FDA) approved Ajovy in September 2018. It is indicated for the preventive treatment of migraine in adults. The medication is used for patients with both episodic migraine (fewer than 15 headache days per month) and chronic migraine (15 or more headache days per month, of which at least eight are migraines). Safety Monitoring and Labeling Updates The FDA monitors the safety of Ajovy through the FDA Adverse Event Reporting System (FAERS). Following its initial approval, regulatory reviews identified potential signals of serious risks, which led to updates in the medication's safety labeling. These updates involve the risk of serious hypersensitivity reactions, including: Anaphylaxis (a severe, life-threatening allergic reaction) Angioedema (swelling of the face, mouth, or throat) Severe rash, hives, or itching According to regulatory information, these allergic reactions can occur within hours of administration or may be delayed by up to one month after an injection. If a serious reaction occurs, the FDA recommends that the medication be discontinued and appropriate medical treatment be started. Regulatory Status Ajovy is a monoclonal antibody that belongs to a class of drugs called calcitonin gene-related peptide (CGRP) antagonists. It is not currently subject to a boxed warning or a Risk Evaluation and Mitigation Strategy (REMS) program. The medication remains under standard post-marketing surveillance to monitor for any new safety concerns.

Question 1

What is Ajovy?

Accepted Answer

Ajovy is a humanized monoclonal antibody that belongs to a class of medications known as calcitonin gene-related peptide (CGRP) antagonists. This medication works by binding to the CGRP ligand, preventing it from interacting with its receptor. CGRP is a protein found in the body that is associated with the transmission of pain signals and the dilation of blood vessels during migraine events.

Question 2

What is Ajovy used for?

Accepted Answer

Ajovy is used to treat migraine prevention.

Question 3

How does Ajovy work?

Accepted Answer

Ajovy belongs to a class of medications called calcitonin gene-related peptide (CGRP) inhibitors. CGRP is a protein found in the brain and nervous system that plays a key role in the development of migraine attacks. During a migraine, levels of CGRP often increase, leading to inflammation and the widening of blood vessels in the brain, which causes pain.

Ajovy works by targeting and binding to the CGRP protein itself. By attaching to this protein, the medication prevents CGRP from binding to its receptors. This action helps to:

Reduce the inflammation associated with migraines.
Prevent the widening of blood vessels that contributes to headache pain.
Block the transmission of pain signals in the brain.

Because Ajovy is a preventive treatment, it is designed to reduce the frequency and severity of migraine attacks over time. It is not intended to stop a migraine that has already begun.

Question 4

What are the active ingredients in Ajovy?

Accepted Answer

The active ingredient in Ajovy is fremanezumab.

Question 5

What are the side effects of Ajovy?

Accepted Answer

Common side effects of Ajovy may include injection site reactions. Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Ajovy?

Accepted Answer

Ajovy belongs to the CGRP antagonist drug class.

Question 7

What is the dosage of Ajovy and how do I take it?

Accepted Answer

Administration

Ajovy is given as a subcutaneous injection, which means it is injected into the fatty tissue just under the skin. It is available as a single-dose pre-filled syringe or a pre-filled autoinjector. Common injection sites include the abdomen, the front of the thighs, or the back of the upper arms. Do not inject into areas where the skin is tender, bruised, red, or hard.

Frequency

This medication is typically used according to one of two schedules:

One injection once every month.
Three injections given together once every three months.

Preparation and Use

Before using Ajovy, remove it from the refrigerator and allow it to sit at room temperature for at least 30 minutes. Do not shake the medication or warm it using a microwave or hot water. Check the liquid to ensure it is clear to slightly yellow and free of particles. If you are injecting multiple doses at once for a quarterly schedule, use a different injection site for each syringe.

Missed Dose

If a dose is missed, it should be administered as soon as possible. After taking the missed dose, the next dose should be scheduled based on the date the last injection was actually given. Do not take a double dose to make up for a missed one.

Question 8

Is Ajovy safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

It is not yet known if Ajovy will harm an unborn baby. There are no adequate or well-controlled studies of Ajovy use in pregnant women to determine drug-associated risks. In animal studies, no evidence of harm to the fetus was observed when the medication was administered during pregnancy. However, because Ajovy is a monoclonal antibody, it may be transferred from the mother to the fetus as the pregnancy progresses.

Breastfeeding

It is unknown whether Ajovy passes into human breast milk, how it affects milk production, or if it has any effect on a nursing infant. Because many medications can be excreted in human milk, you should consult your healthcare provider to weigh the benefits of breastfeeding against the potential risks to the child.

Consulting Your Doctor

If you are pregnant, planning to become pregnant, or breastfeeding, talk to your healthcare team before using this medication. They can help you evaluate your specific situation and determine the most appropriate course of treatment.

Question 9

What forms and strengths does Ajovy come in?

Accepted Answer

Ajovy is supplied as a sterile, preservative-free solution for injection under the skin (subcutaneous use). It is available in the following single-dose formats:

Prefilled autoinjector: A device that automatically delivers the medication when pressed against the skin.
Prefilled syringe: A manual syringe containing a single dose of the medication.

Each device is intended for one-time use only. Once the dose has been administered, the device should be disposed of in a sharps container.

Question 10

What is the FDA approval status of Ajovy?

Accepted Answer

FDA Approval and Indications

The U.S. Food and Drug Administration (FDA) approved Ajovy in September 2018. It is indicated for the preventive treatment of migraine in adults. The medication is used for patients with both episodic migraine (fewer than 15 headache days per month) and chronic migraine (15 or more headache days per month, of which at least eight are migraines).

Safety Monitoring and Labeling Updates

The FDA monitors the safety of Ajovy through the FDA Adverse Event Reporting System (FAERS). Following its initial approval, regulatory reviews identified potential signals of serious risks, which led to updates in the medication's safety labeling. These updates involve the risk of serious hypersensitivity reactions, including:

Anaphylaxis (a severe, life-threatening allergic reaction)
Angioedema (swelling of the face, mouth, or throat)
Severe rash, hives, or itching

According to regulatory information, these allergic reactions can occur within hours of administration or may be delayed by up to one month after an injection. If a serious reaction occurs, the FDA recommends that the medication be discontinued and appropriate medical treatment be started.

Regulatory Status

Ajovy is a monoclonal antibody that belongs to a class of drugs called calcitonin gene-related peptide (CGRP) antagonists. It is not currently subject to a boxed warning or a Risk Evaluation and Mitigation Strategy (REMS) program. The medication remains under standard post-marketing surveillance to monitor for any new safety concerns.

Question 11

What should I know about Ajovy and cost?

Accepted Answer

Factors Affecting Price

Several factors determine the out-of-pocket cost for Ajovy:

Insurance Coverage: Costs are largely determined by your health insurance provider, including your plan's formulary, deductible, and copayment amounts.
Pharmacy Selection: Different pharmacies may have different pricing or may be part of your insurance network.
Dosing Frequency: Ajovy is available in monthly or quarterly dosing schedules, which may affect how often you pay for the medication.

Financial Support Options

Financial assistance may be available for eligible patients:

Manufacturer Savings: A savings card may be available for individuals with commercial insurance to help lower copay costs.
Patient Assistance: Programs may exist to help those without insurance or those who are underinsured access the medication.

Biosimilar Status

Ajovy is a brand-name biologic drug. There are currently no biosimilar versions available, which often means the price remains higher than medications with generic alternatives.

Ajovy

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Ajovy

Hospitals.net Disclosure